Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist with a unique mechanism of action. The glucagon receptor agonist component of survodutide increases energy expenditure and directly affects the liver, potentially helping to improve liver fibrosis. Its GLP-1 receptor agonist component effectively reduces appetite and increases satiety.
